It seems that P could be an adjunctive factor for the production of IL-8; however, SNPs of specific interleukins (IL-1B, IL-17) do not qualify as risk factors in the susceptibility for T1DM and P. More clinical trials are needed on this topic in order to clarify the pathogenetic mechanisms of SNPs in T1DM genesis in patients with and without P. Despite the incomplete knowledge about the full spectrum of interleukin polymorphisms in T1DM, research over the past five years has identified distinct inflammatory pathways that are dependent on unknown factors, requiring more extensive study. This evidence concerns the gene IL17A and type 1 diabetes mellitus.